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ABSTRACT 
Background and Purpose: To evaluate the variation in investigator-delineated volumes and 
assess plans from the radiotherapy trial quality assurance (RTTQA) program of SCALOP, a 
phase II trial in locally advanced pancreatic cancer. 
Materials and Methods: Participating investigators (n=25) outlined a pre-trial benchmark 
case as per RT protocol, and the accuracy of investigators’ GTV (iGTV) and PTV (iPTV) 
was evaluated, against the  trials team-defined gold standard GTV (gsGTV) and PTV 
(gsPTV), using both qualitative and geometric analysis. The median Jaccard Conformity 
Index (JCI) and Geographical Miss Index (GMI) were calculated. Participating RT centres 
also submitted a radiotherapy plan for this benchmark case, which was centrally reviewed 
against protocol-defined constraints. 
Results: Twenty-five investigator-defined contours were evaluated. The median JCI and 
GMI of iGTVs were 0.57 (IQR: 0.51-0.65) and 0.26 (IQR: 0.15-0.40). For iPTVs, these were 
0.75 (IQR: 0.71 to 0.79) and 0.14 (IQR: 0.11-0.22) respectively. Qualitatative analysis 
showed largest variation at the tumor edges and failure to recognize a peri-pancreatic lymph 
node. There were no major protocol deviations in RT planning, but three minor PTV 
coverage deviations were identified. . 
Conclusions: SCALOP demonstrated considerable variation in iGTV delineation. RTTQA 
workshops and real-time central review of delineations are needed in future trials. 
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INTRODUCTION 
Radiotherapy (RT) Trial Quality Assurance (RTTQA) is an important component of radiation 
trials to ensure delivery of high quality treatment and allow consistency in outcome among 
multiple centres [1, 2]. In that context, RT protocols, outlining atlases and benchmark cases 
allow investigators to familiarize themselves with the radiation protocol and demonstrate 
their ability to execute protocol treatment. At least two studies, including one in pancreatic 
cancer, have shown that RT protocol violations may adversely affect overall survival [1, 3]. 
Sub-analysis of the RTOG 9704, a study of adjuvant chemoradiotherapy (CRT) in pancreatic 
cancer showed that the clinical outcome of patients treated as per radiotherapy protocol was 
significantly superior to those treated outside the protocol (overall survival: 1.74 vs. 1.46 
years, p=0.0077; local failure: p=0.016).  
Previous RTTQA studies have principally focused on the quality of radiotherapy plans, with 
little emphasis on testing the quality of tumour outlines [4]. The quality of tumour delineation 
is likely to have major impact on toxicity and survival outcomes [4], especially in a region 
like pancreas where the tumour is often difficult to delineate and is related to critical organs 
at risk (OARs). We therefore wanted to ascertain the degree of variability amongst 
investigator contours within a multi-centre pancreatic radiation trial despite the availability of 
a detailed RT protocol including atlas. We hypothesized that demonstrating a large variation 
in contours would have major implication for conduct of any future pancreatic radiation 
trials, as this would highlight the need for clinician education through regular outlining 
workshops and consideration of real-time central review of tumour contours before trial 
participants begin radiotherapy.  
The Selective CRT in Advanced Localized pancreatic cancer study (SCALOP I, EudraCT 
No: 2008-001394-1) was a multi-centre randomized phase II trial where patients received 
four months of gemcitabine/capecitabine chemotherapy followed by randomization to either 
gemcitabine- or capecitabine-based CRT [5]. One hundred fourteen patients from 28 centres 
were registered, and 74 received CRT. Radiotherapy consisted of 50.4Gy in 28 fractions 
delivered conformally; dose of concomitant gemcitabine was 300mg/m
2 
weekly and dose of 
capecitabine was 830mg/m
2 
administered twice daily on days of radiotherapy. Pre-trial 
component of the SCALOP RTTQA included a pretrial benchmark case. The principal 
radiation oncologists from centres participating in the trial were required to outline the 
tumour volumes, and corresponding RT plans were also submitted. Herein we report the 
variation in investigator outlines and quality of RT plans from the bench-mark case of the 
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SCALOP trial. We also evaluated the applicability of a novel concept, the planning 
assessment form (PAF), a paper-based proforma which allowed rapid, real-time review of 
adherence to protocol constraints.  
 
MATERIALS AND METHODS 
SCALOP trial RTTQA program 
The details of the SCALOP RTTQA Program are described in Supplementary Methods, and 
the full protocol can be accessed at http://www.wctu.org.uk/trial.php?trial=scalop. The 
protocol had a detailed radiotherapy section including a detailed slice-by-slice atlas of 
delineated ‘head’ and ‘body/tail’ tumours and organs at risk. The study also required the 
participating centres to outline and plan a ‘benchmark case, from a patient with a pancreatic 
head tumour scanned as per the SCALOP RT protocol, reviewed and agreed by the SCALOP 
RTTQA group. The planning CT scan dataset in Digital Imaging and Communications in 
Medicine (DICOM)-RT format was sent to all participating centres for tumour volume 
delineation by the principal radiation oncologist investigator, with input from a radiologist 
with expertise in gastrointestinal cancer. All investigators (n=25) were asked to follow the 
trial protocol and outline the gross tumor volume (iGTV) and create a planning target volume 
(iPTV) directly from the iGTV by the addition of treatment planning system (TPS) generated 
margins as per the SCALOP protocol: 2.0cm in superior-inferior direction and 1.5cm in all 
other directions. The centers also generated a plan following the protocol stipulated 
dose/volume constraints and filled in a planning assessment form (PAF - described in 
Supplementary Methods; shown in Supplementary Figure 1). In summary, the PAF was a 
tabulated form where protocol-specific dose constraints were pre-populated with 
corresponding spaces to allow the investigator to record the constraint dose achieved in that 
particular case. The pre-populated values served as a quick check-list of the protocol 
constraints to ensure these limits were not breached. Once completed, the DICOM-RT dataset 
including all outlined target volumes and organs at risk (OARs), the 3D dose cube and the 
PAF were submitted for central review.  
 
Review of tumour outlines of the test case 
In order to facilitate review of tumour outlines, a ‘gold standard’ set of reference structures 
(gsGTV, gsPTV) were created by the Chief Investigator (SM) and the Chief trial radiologist 
(GJ). The iGTVs and iPTVs of the individual investigators (n=25) were compared against 
gsGTV and gsPTV using qualitative and geometric analysis.  
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Qualitative Analysis  
For qualitative analysis, the n=25 DICOM-RT datasets from the 25 centers that participated 
in the pre-trial benchmark contouring case (one investigator per center) were individually 
imported into the ImSimQA
contour
 software (Oncology Systems Limited,UK), allowing 
superposition of investigator contours against the gsGTV and gsPTV. Three reviewers, 
including a gastrointestinal radiologist, visually evaluated each iGTV against the gsGTV on a 
slice-by-slice basis. Each slice of each iGTV was scored as significant over-contour 
(outlining of unequivocal OAR, usually normal pancreas, stomach or duodenum), significant 
under-contour (omission of unequivocal tumor) or as acceptable variation (outlining variation 
within acceptable limits on visual inspection, where the deviation from the gold standard was 
felt to be unlikely to result in compromised tumour control, or excessive toxicity). 
 
Geometric Analysis 
For quantitative analysis, the investigators' DICOM-RT datasets were individually imported 
into Computational Environment for Radiotherapy Research (CERR) [6]. CERR was used to 
assess the whole volume iGTVs and iPTVs for over- and under-outlining compared to the 
respective gold standard volumes. We used the Jaccard Conformity Index (JCI) and 
Geographical Miss Index (GMI) [7], defined in Supplementary Table 1. The iGTV was then 
re-analyzed in CERR on a slice-by-slice basis generating the JCI, GMI and Mean Distance to 
Conformity (MDC) for each slice as we described previously [8, 9].  
 
Review of RT planning of the test case  
The DICOM-RT planning datasets for each submitted contour were centrally reviewed using 
the Visualization and Organization of Data for Cancer Analysis program (VODCA 4, 
Medical Software Solutions, Hagendorn, Switzerland), a research software that can read 
DICOM-RT datasets from multiple planning systems. Plan quality and adherence to dose 
volume constraints were assessed. We also evaluated the accuracy of PAF completion by 
comparing figures enumerated on PAF against the actual dose values generated from 
VODCA. Investigating centers were provided individualized written feedback on the 
performance of the benchmark case. Real-time central review of each patient’s iGTV was not 
conducted but on-trial review of radiotherapy planning was performed through assessment of 
the PAF before each patient received radiotherapy. There was high compliance to all aspects 
of dose prescription to PTV with only three minor deviations reported using the PAF (Table 
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1); all of these were in the volume of PTV receiving 95% of the prescribed dose falling below 
the required 99% (95.1%, 96.7% and 97.6%, respectively). 
 
Statistical Analysis 
The Stata 13 package (StatCorp LP, College Station, Texas, USA) was used to conduct 
statistical analyses. Variables were assessed for their normality using the Shapiro-Wilk test 
before summary statistics and a number of correlations were assessed. For variables that were 
normally distributed the mean and standard deviation (SD) were cited and the Pearson 
correlation coefficient (R) was used. For the variables that were not normally distributed the 
median and interquartile range (IQR) were cited and the Spearman correlation coefficient 
(Rho) used.  
 
RESULTS 
Qualitative review of tumour outlines of the test case 
The volumes of the n=25 investigators were assessed. The gsGTV extended over twelve 
3mm slices. Qualitative review of contours identified several areas showing poor agreement 
between iGTV and gsGTV. Under-contouring errors were most common with five centers 
significantly under-contouring on ≥10 slices. In the central section of the tumor, 23 
investigators missed a peritumoral lymph node on two slices (Figure 1A). The peritumoral 
lymph node was included in the PTV in all cases. The other main area of significant under-
contouring was at the inferior end of the tumor where 19 centres failed to contour a small 
area around the superior mesenteric artery (Figure 1B). Eight investigators systematically 
over-contoured the duodenum on multiple slices, with five centres significantly over-
contouring on >10 slices. Over-contouring of the duodenum was the most common error 
(Figure 1C). In two cases, investigators had to resubmit as the contours were felt to be 
unacceptable – one investigator had outlined the bile 
duct above the tumor as iGTV and the other had outlined almost the whole of the second part 
of the duodenum within the iGTV. 
 
Geometric Analysis of the whole volume 
The iGTV volumes, with the corresponding GMI and JCI data, for all investigators are shown 
in Figure 2a. The volume of gsGTV and gsPTV were 26.3 cm
3
and 223.3 cm
3
, respectively. In 
comparison, the median iGTVs and iPTVs were 23.2cm
3 
 (IQR: 17.2-32.5) and 209.5 cm
3
 
(IQR: 183.1-234), respectively. The ratio of the largest to the smallest iGTV and iPTV was 
7 
6.8 and 2.8, respectively. The median whole volume JCI of the iGTVs compared to gsGTV 
was 0.6 (IQR: 0.5-0.7) and the median GMI was 0.3 (IQR: 0.15-0.4). For iPTVs, the median 
JCI was 0.75 (IQR: 0.7-0.8) and the median GMI was 0.1 (IQR: 0.1-0.2). Additionally, the 
GTV was highly linearly correlated with GMI (Rho = -0.9), as less GTV is missed as volume 
increases. JCI and GTV volume (Figure 2a) have a more complex, bell-shaped relationship 
with lower JCI scores with higher or lower iGTV volumes, as JCI falls with both over and 
under-outlining errors. A similar relationship is shown for PTV volume and GMI (Rho = -
0.9) and JCI (Figure 2b). The slice by slice analysis of conformity between each iGTV and 
the gsGTV performed in CERR is described in Supplementary Results and shown in 
Supplementary Figure 2.  
 
Review of RT planning of the test case  
The protocol advised complete sparing of one kidney, where possible, which was achieved by 
13 centres that restricted the contralateral kidney Dmax to less than 2%. Additionally, we 
imported the planning values into VODCA and compared them to the PAF (Figure 3A-F). In 
total, values from 22 investigators were available. Two centres recorded the maximum dose 
to spinal cord as the percentage of the prescription dose as opposed to the requested absolute 
dose i.e. 18.6Gy in VODCA and 37.1% on PAF. Unexpectedly, four centres misidentified the 
ipsilateral kidney, erroneously recording the dose to the left kidney on the PAF in patients 
with pancreatic head tumours. Finally, with regard to the outlining of the OAR, the volumes 
of outlined structures from the approved cases are shown in Supplementary Table 3. Despite 
all iGTVs being approved, considerable variation remained. 
 
DISCUSSION 
Quality assurance is necessary for safe and effective delivery of radiation. A systemic review 
identified only nine phase II-III RT studies published between January 1994 and December 
2011 that reported clinical outcomes of a RTTQA program of which only two trials had a 
prospective interventional QA process [4]. Studies reporting impact of RTTQA on clinical 
outcome showed worse survival in patients who had major protocol deviations [10]. The 
overall rate of protocol compliance was 65% (2309 evaluable patients) and 13% of the trials 
had a ‘deviation unacceptable’ rate >10%. Previous studies incorporated a pre-treatment 
review of radiotherapy planning – all of these studies showed enhanced protocol adherence 
[10]. The importance of RTTQA has led to international collaboration of RTTQA processes 
[11, 12]. 
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Whereas adherence to radiotherapy protocol undeniably improves patient outcome, RTTQA 
programs have primarily focused on dosimetry and other components of treatment delivery. 
Over and under-contouring errors are highly likely to impact toxicity and efficacy outcomes, 
but accuracy of GTV outlining has not been prospectively evaluated in many pancreatic trials 
[4, 11]. Consistency of GTV outlining is especially important in multi-centre trials of high 
dose radiotherapy (including stereotactic radiotherapy), where small margins are applied and 
therefore inappropriate delineation may result in geographic miss or serious gastro-intestinal 
toxicity. 
The SCALOP trial results suggested that outcome with the capecitabine-based regimen was 
preferable to the gemcitabine-based regimen as it was associated with superior survival and 
lower toxicity [5]. We believe that the high quality of RTTQA within SCALOP contributed 
to these results and have laid the foundation for future trials in this disease. To our best of 
knowledge, SCALOP is the first multicenter pancreatic trial that has comprehensively 
assessed the variation in investigator-defined contours using qualitative as well as conformity 
indices in a prospective manner. In the present study, we found poor agreement in iGTV 
delineation amongst 25 investigators and the corresponding largest: smallest ratio was 6.8. 
Importantly, this variation occurred despite the availability of a detailed RT outlining 
protocol, trial-specific clinical atlas and input from radiologists. For the tumour itself, there 
was greatest concordance in the central sections and the uncertainty lay in defining the 
superior and inferior borders. A peritumoral lymph node was, however, missed by 23 
investigators.  
An older study reported variation in investigator-delineated iGTV in locally-advanced 
pancreatic cancer (LAPC) following assessment of the outlines of 11 radiation oncologists 
from eight institutions [13]. The ratio of the largest: smallest iGTV contour was 9, with a 
median iGTV of 31.8cm
3
 for head tumor; a ratio of 3.3 with a median iGTV volume of 67.9 
cm
3
 for body tumor. However, conformity indices were not used and, in contrast to our trial, 
a detailed RT planning protocol was lacking [13]. In a recent work, Caravatta et al examined 
the inter-observer variability in clinical target volume contouring by using the coefficient of 
variation and the Dice Similarity Index in two dummy runs and revealed acceptable 
agreement among participating physicians [14]. 
This work supports the findings of Gwynne et al. [9] who studied investigator variation in 
target delineation in the SCOPE 1 esophageal trial that proposed the concept of slice 
conformity indices as a tool to identify areas of maximum discrepancy. Our work confirms 
the utility of slice MDC as a sensitive index that could be used to direct more detailed review. 
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The completion of the PAF for the pre-trial benchmark identified two areas of 
misunderstanding in the protocol. Four of 23 centres mis-identified the kidneys as 
contralateral/ipsilateral. The PAF asked centres to report both the volume of the PTV 
receiving 95% of the prescription dose (47.9Gy), which a constraint of 99% and the PTV 
minimum dose, for which there was no clear constraint: ‘The aim should be to encompass the 
PTV with the 95% isodose. Although in routine clinical practice this is generally taken to 
mean that the absolute minimum PTV dose should always be >90% and ideally >93%, we 
should have made this a constraint. There was also excellent compliance to the other aspects 
of the protocol, with no cases exceeding OAR dose constraints. This highlights the preference 
for PTV underdose rather than OAR overdose. Altogether, the pre-trial educational package 
and RTTQA program ensured a comprehensive understanding of the radiation protocol, as 
suggested by the benchmark case and highlight the importance of RTTQA to facilitate high-
quality clinical trials.  
Given the variability seen with CT-based planning, the role of integrating additional imaging 
modalities, such as FDG-PET, in pancreatic radiotherapy planning warrants investigation. In 
one study where CT-based GTVs were compared with co-registered FDG-PET-based GTVs, 
five of 14 patients required changes based on PET-CT information [15].The average GTVs 
increased by 29.7%, mainly due to addition of lymph node metastases and extension of 
primary tumor beyond that defined by CT. We have recently conducted a pilot study 
comparing GTV delineation using CT versus FDG-PET [16]. This showed a reduction in the 
standard deviation and range of volumes in favor of PET-CT [16].  
Our study had several limitations. First, the use of a single oncologist-radiologist team to 
outline gsGTV was a potential limitation as it was subject to bias. In hindsight, the use of a 
consensus outline by a group of national experts, as proposed by Myerson et al. [17] may 
have been more appropriate. Secondly, despite the well-defined planning and RTTQA criteria 
and the assistance by a radiologist, variability in iGTVs was observed that may reflect a lack 
of extensive clinical experience in outlining for pancreatic RT. Third, we did not assess 
whether the variation in outline decreased with time as centres gained more experience with 
pancreatic radiotherapy contouring. Irrespective, the study does highlight that measures need 
to be taken to account for inter-observer variation, possibly through the use of interactive on-
treatment real-time contour reviews, and intensive contouring workshops involving 
participating investigators. It should be mentioned that our study is based on only one patient.  
In summary, our data demonstrated inter-observer variability in GTV contouring despite the 
availability of a detailed RT protocol, educational atlas and the radiologist’s input. 
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Altogether, our RTTQA, which included the use of PAF, ensured adherence to the 
radiotherapy planning protocol in the majority of cases, with all identified deviations being 
minor. Our data provide valuable insight on the importance of well-defined RTTQA and 
contouring guidelines in the radiotherapy of LAPC. More intense RTTQA, including 
radiotherapy workshops and real-time central review of delineated GTVs should be 
considered in future trials.  
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FIGURE LEGENDS 
Figure 1. Examples of the investigating centers gross tumor volumes (iGTVs), pink, and the 
gold standard gross tumor volumes (gsGTV), yellow, on slices that caused the most common 
under- and over-contouring errors. A geographical miss of the peritumoral lymph node (red 
arrow) was observed for 23 of 25 investigators (Figure 1A). ). At the inferior end of the 
tumor, 19 centers failed to contour a small area around the superior mesenteric artery (Figure 
1B). Over-contouring of the duodenum was the most common error (Figure 1C). 
 
Figure 2. Scatter plot showing the correlation of the Geographical Miss Index (GMI) and the 
Jaccard Conformity Index (JCI) with A) the investigator gross tumor volumes (iGTVs) and 
B) the investigator planning target volumes (iPTVs).  
 
Figure 3. Illustration of the relationship between planning assessment form (PAF) value and 
the Visualization and Organization of Data for Cancer Analysis program (VODCA) values 
for benchmark cases, as indicated (A-F). Two minor deviations of dose constraints were 
identified from the PAF for PTV D95 (<99%) (black data points) (A). VODCA values for 
maximum dose to spinal cord was significantly lower than the PAF value in 2 cases (black 
data points).e.g. 18.6 in VODCA and 37.1 on PAF. However, 18.6Gy is 36.9% of the 
prescription dose and this value would agree with that written on the PAF (B). Incorrect 
identification of the ipsilateral kidney occurred in four cases (black data points) (C). 
 
 
 
Figure 1 
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B 
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Table 1. Dose to PTV and OARs from benchmark case  
Structure/ 
Dose 
Constraint Gold 
Standard  
PAF values (N=22 cases) 
Mean (SD) Minor 
deviations 
Major 
deviations 
PTV D95 (%) >99.0% 99.9% 
99.2% (1.3) 
3  none 
PTV Dmin 
(%) 
Not 
defined  
94.1% 
90.3 
% (13) 
N/A N/A 
ICRU defined 
maximum 
dose (%) 
107% 103.4% 103% (1.3) none none 
Liver V30 
(%) 
<40% 5.4% 7.3% (4) none none 
Ipsilateral 
Kidney 
V20 (%) 
<40% 1.0% 7.7% (7.2) none none 
Combined 
Kidney V20 
(%) 
<30% 1.4% 5.5%  (6) none none 
Spinal cord 
PRV Dmax 
(Gy) 
<40Gy 0 21.7Gy  (8.2 
) 
none none 
!
!
!
